Weekly blood draws to study fluctuations in Alzheimer's biomarkers
Draw-10: A Weekly Blood Draw Study to Understand the Biological Variability of Plasma pTau-217
This study collects blood samples from people with normal thinking or mild memory issues over nine weeks to see how Alzheimer's-related markers in the blood change, helping to improve how we use blood tests for diagnosing and tracking the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | Banner Health Academic / other |
| Locations | 2 sites (Phoenix, Arizona and 1 other locations) |
| Trial ID | NCT06742944 on ClinicalTrials.gov |
What this trial studies
This observational study collects 10 plasma samples from participants over 9 weeks to analyze the variability of blood biomarkers related to Alzheimer's disease. By assessing these fluctuations, the study aims to better understand how blood biomarkers can be reliably used in clinical practice for diagnosing and monitoring Alzheimer's. The research focuses on individuals with normal cognition or mild impairment, ensuring a targeted approach to understanding biomarker behavior. The findings could help refine the use of blood tests in routine dementia evaluations.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50-80 with normal cognition or mild cognitive impairment who can provide informed consent.
Not a fit: Patients currently enrolled in other clinical trials using investigational drugs or those planning new treatments during the study period may not benefit.
Why it matters
Potential benefit: If successful, this study could enhance the reliability of blood biomarkers for diagnosing and monitoring Alzheimer's disease.
How similar studies have performed: While blood biomarkers for Alzheimer's are increasingly adopted, this specific approach to studying their fluctuations is novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * able and wiling to provide informed consent * Aged 50-80 years old at the time of signing study consent; participants aged 50-59 years will be no more than 20% of the total study population * Has normal cognition or mild impairment at screening MoCA by a score of greater than or equal to 18; participants with a Montreal Cognitive Assessment (MoCA Test) score between 18-25 will be no more than 20% of the total study population * able and wiling to fully comply with study procedures defined in the protocol * Written and spoken fluency in English Exclusion Criteria: * Plans to begin any new treatment or is having surgery during the 9-week draw timeframe * Currently enrolled in a clinical trial using an investigational drug
Where this trial is running
Phoenix, Arizona and 1 other locations
- Banner Alzheimer's Institute — Phoenix, Arizona, United States (Recruiting)
- Banner Alzheimer's Institute Tucson — Tucson, Arizona, United States (Recruiting)
Study contacts
- Principal investigator: Jessica B Langbaum, PhD — Banner Alzheimer's Institute
- Study coordinator: Central Recruiting
- Email: draw10@bannerhealth.com
- Phone: 602-839-6500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.